Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHRONVAC-C + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- ChronTech Pharma
- Modality
- Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous (peginterferon Alfa-2a), Oral (ribavirin), Intramuscular (chronvac-c, As Used In Trials)
01
Overview
CHRONVAC-C + peginterferon alfa-2a + ribavirin is a **combination therapy** used in clinical trials for the treatment of chronic hepatitis C virus (HCV) infection. CHRONVAC-C is a DNA vaccine candidate targeting hepatitis C virus, designed to promote host immune response against HCV. Peginterferon alfa-2a is a pegylated interferon that binds to type I interferon receptors, triggering antiproliferative and immune-modulating effects, and ribavirin is a nucleoside analogue that enhances the antiviral effects of interferon through mechanisms such as direct inhibition of viral replication and suppression of viral RNA synthesis. Peginterferon alfa-2a plus ribavirin is a well-established first-line treatment for chronic hepatitis C, producing significantly higher sustained virologic response rates than earlier regimens, especially for genotype 2/3, with typical routes of administration being subcutaneous injection for peginterferon and oral for ribavirin[1][3][5][7]. The addition of CHRONVAC-C aims to further stimulate the immune response, but specific outcomes, safety profile, and approval status for this triple combination are primarily available in clinical trial contexts.
- Brand names
- ChronVac-C
- Other names
- CHRONVAC-C
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)HCV E2 (Hepatitis C virus envelope glycoprotein E2)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on CHRONVAC-C + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHRONVAC-C + peginterferon alfa-2a + ribavirin.